AWM
ALT icon

Avior Wealth Management’s Altimmune ALT Stock Holding History

Avior Wealth Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12
Closed -$122 – 2308
2024
Q1 		$122 Buy
+12
New +$122 ﹤0.01% 3100

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Avior Wealth Management's ALT Position: Q2 2024 in Review

Avior Wealth Management sold out of Altimmune (ALT) in Q2 2024, closing a stake of 12 shares — an estimated $122 sold.

Avior Wealth Management first reported a position in ALT in Q1 2024 and held it in 1 quarter. The position peaked at $122 in Q1 2024. 173 funds tracked by Wall St. Rank hold ALT as of Q2 2024.

  • Avior Wealth Management reported no remaining Altimmune position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 12 Altimmune shares in Q2 2024, an estimated $122.
  • Avior Wealth Management first reported a position in Altimmune in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Altimmune position peaked at $122 in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.